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HIV-1 circulates within an infected host as a genetically heterogeneous viral population. Viral intrahost
diversity is shaped by substitutional evolution and recombination. Although many studies have speculated that
recombination could have a significant impact on viral phenotype, this has never been definitively demon-
strated. We report here phylogenetic and subsequent phenotypic analyses of envelope genes obtained from
HIV-1 populations present in different anatomical compartments. Assessment of env compartmentalization
from immunologically discrete tissues was assessed utilizing a single genome amplification approach, mini-
mizing in vitro-generated artifacts. Genetic compartmentalization of variants was frequently observed. In
addition, multiple incidences of intercompartment recombination, presumably facilitated by low-level migra-
tion of virus or infected cells between different anatomic sites and coinfection of susceptible cells by genetically
divergent strains, were identified. These analyses demonstrate that intercompartment recombination is a
fundamental evolutionary mechanism that helps to shape HIV-1 env intrahost diversity in natural infection.
Analysis of the phenotypic consequences of these recombination events showed that genetic compartmental-
ization often correlates with phenotypic compartmentalization and that intercompartment recombination
results in phenotype modulation. This represents definitive proof that recombination can generate novel
combinations of phenotypic traits which differ subtly from those of parental strains, an important phenomenon
that may have an impact on antiviral therapy and contribute to HIV-1 persistence in vivo.
Approximately 33 million people globally are infected with
HIV-1 group M viruses, with an estimated 2.5 million new
infections in 2007 (87). The extreme diversity of HIV-1 is
characterized by nine phylogenetically distinct subtypes and a
multitude of circulating recombinant forms (CRFs) (6). Such
diversity poses a significant obstacle for the development of a
successful prophylactic vaccine (21, 82). HIV-1 circulates
within an infected host as a genetically heterogeneous viral
population. The rapid rate of HIV-1 diversification within an
infected individual is driven, in part, by the error-prone nature
of HIV-1 reverse transcription and the high replicative rate in
vivo that facilitates the incremental accumulation of insertions,
deletions (indels), and point mutations in the viral genome
(36). The inherent genetic variability of the population leads to
humoral (86) and cellular (31) immune escape, resistance to
antiretrovirals (9), and altered cytopathogenicity and cell tro-
pism (48–50). Compartmentalization of HIV-1 populations de-
rived from a range of tissues has been reported, including
blood versus brain/central nervous system (1, 27, 47, 53, 67),
brain versus lymph (4, 42, 68), blood versus female genital tract
(51), and blood versus semen (10, 12, 24, 52, 93). In addition,
genetic segregation of HIV-1 variants is also apparent between
different populations of Langerhans cells (61) and at different
sites within the brain (63), spleen (11), and gut (79). Such
compartmentalized variation is shaped by a combination of
founder effect, restricted cellular/viral trafficking between seg-
regated subpopulations and local environmental selective pres-
sures, including receptor/cellular tropism and tissue-specific
immune responses.
A large part of HIV-1’s genomic variability is located within
the env gene, which encodes the transmembrane glycoprotein
gp41 and surface glycoprotein gp120. These glycoproteins exist
as trimeric spikes of gp41-gp120 heterodimers on the surface
of the viral membrane (34, 92). Progressive evolution of the
env gene contributes to escape from host immune responses.
However, these processes are restricted by functional con-
straints associated with receptor and coreceptor binding and
membrane fusion. The interaction of gp120 with the primary
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cellular receptor CD4 results in major conformational changes
in the env trimer (34), which facilitates subsequent binding to
the chemokine coreceptors CCR5 (8) and/or CXCR4, fol-
lowed by gp41-mediated membrane fusion.
HIV-1 genetic heterogeneity is also shaped by recombina-
tion and mosaicism. HIV-1 is a highly recombinogenic virus,
with exchange of genetic material between divergent group M
subtypes giving rise to multiple CRFs worldwide (6, 56, 57).
Examples of both inter- and intrasubtype recombinants have
been reported (2, 6, 35, 58). Molecular epidemiological studies
demonstrate rapid dissemination of certain CRFs in specific
geographical localities (33, 77), suggesting that in some settings
a fitness advantage may be conferred by mosaic genomes (3).
However, this has not been definitively demonstrated. Recom-
bination occurs via reverse transcriptase template switching
during proviral DNA synthesis. Consequently, this phenome-
non can only occur when a target cell is dually infected by
genetically discrete viral strains (36, 56, 57). At the intrapatient
level, recombination events continually produce mosaic ge-
nomes (7, 45). The rate of HIV-1 recombination has been
shown to significantly exceed the rate of nucleotide misincor-
poration by the viral reverse transcriptase per round of genome
replication (25, 39). Moreover, rates of HIV-1 recombination
have been shown to differ between infected cell types (32).
Intrapatient recombination has been proposed to facilitate re-
sistance to targeted antiretroviral therapies (7, 44), as well as
alter the tropism of resistant viruses during therapy (69). Ex-
change of genetic material between viruses isolated from the
blood and female genital tract has also been demonstrated
(51). However, despite its widespread documentation, no stud-
ies have definitively demonstrated that naturally occurring re-
combination can lead to altered viral phenotype.
To determine the relative contribution of intercompartment
recombination to intrahost HIV-1 genetic variability, as well as
determine its phenotypic consequences, we characterized
HIV-1 env genes, obtained by single genome amplification
(SGA), present in different anatomical compartments. Char-
acterization of intrahost diversity by sequence analysis of SGA
products excludes polymerase-induced nucleotide misincorpo-
ration, amplicon resampling, cloning bias, and the generation
of in vitro recombinants via polymerase template switching (62,
70). High-resolution analyses of the sequence data revealed
the presence of intercompartment recombinant viruses. Im-
portantly, these recombination events conferred altered and
potentially advantageous phenotypes compared to compart-
mentalized nonrecombinant strains.
MATERIALS AND METHODS
Sample collection and preparation. Paired blood and semen samples were
acquired from four treatment-naive HIV-1 men attending clinics in Tiko, Cam-
eroon, and Birmingham, United Kingdom. Blood and seminal plasmas were
prepared by centrifugation at 1,500  g for 20 min and stored at 70°C prior to
RNA extraction. Seminal fluid mononuclear cells (SFMC) and peripheral blood
mononuclear cells (PBMC) were isolated by centrifugation and Ficoll density
gradient centrifugation, respectively. Washed PBMC and SFMC pellets were
resuspended in 250 l of saline prior to total DNA extraction (22). Paired
samples were collected on the same day for each individual patient and pro-
cessed within 4 h. Brain and cervical lymph node tissue were obtained at autopsy
in Birmingham, United Kingdom, from a single HIV-1 patient who died of
AIDS related complications and stored at 70°C prior to total DNA extraction.
Sample collection and subsequent research on all patient tissue utilized in the
present study received ethical approval by the West Midlands Local Ethics
Committee (United Kingdom) and the National Ethics Committee (Cameroon).
All participants gave written informed consent.
Nucleic acid extraction and cDNA synthesis. Viral RNA was extracted from
blood and seminal plasma samples by using a QIAamp viral RNA kit (Qiagen)
according to the manufacturer’s instructions. Total DNA was extracted from
PBMC, SFMC, brain autopsy, and lymph node autopsy samples by using a
Stratagene DNA extraction kit according to a previously described, modified
version of the manufacturer’s protocol (4, 41). A gene-specific primer (20) was
used to reverse transcribe cDNA from each RNA sample using a Thermoscript
kit (Invitrogen) according to the manufacturer’s instructions.
PCR amplification of env from single molecule templates. Due to high levels
of circulating HIV-1 diversity apparent in Cameroon, nested primer pairs shown
to be effective at amplifying env from a diverse range of subtypes were used (20)
according to previously described conditions (62). Accurate and representative
sampling of the env intrahost diversity was achieved via SGA to preclude gen-
eration of in vitro artifacts (42, 62, 70). Amplicons were sequenced via BigDye
terminator chemistry using an ABI 3100 capillary sequencer. Sequence chro-
matographs were manually inspected, and amplicons generated from 1 cDNA/
provirus molecule were excluded from subsequent analyses. Amplicons that
showed evidence for APOBEC3G-induced G-to-A hypermutation (37, 59, 65) or
exhibited 1 example of a translation terminating stop codon or a frameshift
inducing indel were also omitted. Subtype/CRF designations were determined by
using the REGA subtyping tool (13). Sequences generated for the present study
have been submitted to GenBank under accession numbers JF706370 to
JF706501.
Sequence alignment and phylogenetic reconstruction. Nucleotide sequences
were aligned, with manual editing, according to overlying amino acid sequence
using the CLUSTAL W algorithm implemented in MEGA4 software (76). Re-
gions of ambiguous alignment were gap stripped from patient-specific and com-
TABLE 1. Patient and sample information
Patient Sampling location Isolation date(day/mo/yr) Risk factor
a CD4 count
(mm3)
Infecting
subtype/CRF Treatment Sample material
Virus genetic
material
E21 United Kingdom 08/04/1991 MSM 120 B AZT Lymph node autopsy DNA
Brain autopsy DNA
UKBH1 United Kingdom 18/07/2007 MSM 323 B None Blood plasma RNA
Seminal plasma RNA
Blood PBMC DNA
Semen SFMC DNA
KM11 Cameroon 17/06/2005 Hetero 3 CRF02 None Blood plasma RNA
Seminal plasma RNA
KM18 Cameroon 17/06/2005 Hetero 154 CRF02 None Blood plasma RNA
Seminal plasma RNA
KM34 Cameroon 27/03/2006 Hetero 251 Ub None Blood plasma RNA
Seminal plasma RNA
a MSM, men having sex with men; Hetero, heterosexual.
b U, the env gene did not correspond to any described group M subtype/CRF.
VOL. 85, 2011 INTRAHOST RECOMBINATION MODULATES HIV-1 PHENOTYPE 6025
6026 BROWN ET AL. J. VIROL.
bined alignments. Pairwise distance matrices were calculated for compartment-
specific env alignments via the maximum-composite-likelihood method
implemented in MEGA4 software. Values were plotted in Prism GraphPad. A
maximum-likelihood (ML) phylogenetic tree was generated for the combined
alignment using the PHYML program (23) under the best-fit model of nucleo-
tide substitution calculated by Modeltest (55) and midpoint rooted. Bootstrap
values were derived from 1,000 replicate neighbor-joining trees (60), and signif-
icant (70%) values were assigned to internal ML tree branches.
Recombinant identification. Patient-specific alignments were subsequently di-
vided into three segments containing equal numbers of variable sites, and 1,000
partition-homogeneity test replicates were conducted using PAUP* v4.0b10 (75).
A P value for the congruence of phylogenetic trees derived from different regions
of the env gene was subsequently obtained for each patient’s viral population
(19). ML trees were then generated for each patient’s three env region align-
ments under the best-fit model of nucleotide substitution using PAUP* v4.0b10.
Topologies were inspected for significant positional switching of isolates between
clades in different regions of env. Amplicons that exhibited shifting between
compartment-specific clades were further investigated for mosaicism using a
combination of pairwise diversity plots and informative site arrays (56, 72) as
implemented in SimPlot version 3.5.1 (35). Breakpoint P values were calculated
via 1,000,000 random shuffles of the order of sites of each informative sites array,
with the significance test asking how often pseudoreplicate arrays are generated
with a breakpoint as high as 2 values obtained with the real data. Absolute
breakpoint coordinates were derived from diversity plot crossover points. Only
mosaics composed of identifiable parental strains were characterized.
Cloning of env amplicons for phenotyping. The phenotypic consequences of
intercompartment recombination were subsequently investigated in patients E21
and KM34. Although intercompartment mosaicism was detected in patient
KM11, we were unable to clone these env amplicons, despite numerous attempts
using a variety of cloning procedures. Therefore, we were unable to perform
phenotypic characterization of envelope genes from this patient. Previous phe-
notypic studies of subtype B primary isolate env genes (86) report successful
pseudovirion production using rev1/env cassettes ligated into appropriate expres-
sion vectors. Consequently, env amplicons were fused with HXB2 rev1 using an
in-house recombinant PCR methodology. Briefly, amplification reactions were
set up in 25-l volumes containing 5 pmol of primer HXB2_RE_S (5-CACC
CAAAAGCCTTAGGCATCTCC-3), 5 pmol of primer HXB2_RE_AS (5-T
CACACTACTTTTTGACCACTTGC-3), 200 mM deoxynucleoside triphos-
phates, 0.5 U of Phusion high-fidelity DNA polymerase (Finnzymes), 1
Phusion HF buffer, and 250 pg of HXB2 full-length genome containing plasmid
template. The PCR cycling parameters consisted of an initial denaturation step
at 98°C for 30 s, followed by 35 cycles of 98°C for 10 s, 66°C for 15 s, and 72°C
for 15 s, with a final extension step at 72°C for 1 min. Equimolar amounts of
HXB2 rev1 and SGA-derived env amplicons were then used as a template for a
recombinant PCR amplification using the primers HXB2_RE_S and envM (20)
according to the reaction setup conditions outlined above. Recombinant PCR
was achieved via a two-step cycling strategy. Cycling parameters were an initial
denaturation step at 98°C for 30 s, followed by 35 cycles of 98°C for 10 s and 72°C
for 45 s, with a final extension step at 72°C for 1 min. The resulting rev/env
cassettes were ligated into pcDNA3.1 D-TOPO (Invitrogen), confirmed by se-
quencing, and transformed in TOP10 or STBL3 cells (Invitrogen).
Cell cultures. HeLa TZM-BL cells were used to titrate env pseudovirions and
to evaluate HIV-1 neutralization (54, 85). Macrophage cultures were prepared
from elutriated (26) or blood monocytes (48) as described previously. HEK 293T
cells (15) were used to prepare env pseudovirions by transfection.
Production and titration of env pseudovirions. Both a pNL4.3 construct
lacking env and an env pcDNA3.1 D-TOPO expression vector were used to
produce env pseudovirions as described previously (48, 50).
Infectivity assays. Infectivity assays were performed as previously described
(16). Primary macrophages were treated with DEAE dextran (10 g/ml) prior to
infection, before addition of an equal volume of serially diluted env pseudovi-
rons and spinoculation (46). HeLa TZM-BL cells were infected without DEAE
dextran or spinoculation.
Inhibition and neutralization assays. Inhibition and neutralization assays for
sCD4 (49) and neutralizing monoclonal antibodies b12 (91) and 2G12 (64) were
carried out as described previously using HeLa TZM-BL cells as target cells (16,
49). For maraviroc, a CCR5 receptor antagonist (14), cells were treated with
2-fold dilutions in 50 l for 30 min before adding an equal volume containing 200
FFU of pseudovirus. After 3 h at 37°C, the virus-antibody mixture was removed,
growth medium was added, and infected cells were incubated at 37°C for a total
of 48 h. To evaluate residual infectivity, the medium was removed, and 100 l of
medium without phenol red was added. The cells were then fixed and solubilized
by adding 100 l of Beta-Glo (Promega, Inc.). Luminescence was then read in a
BioTek Clarity luminometer.
RESULTS
Tissue panel and generated env amplicons. Paired HIV-1
patient tissue samples included blood and semen from treat-
ment-naive Cameroonian and United Kingdom patients at dis-
tinct disease stages, in addition to archival brain and lymph
node autopsy samples from a United Kingdom patient who
died of AIDS related complications (Table 1). PCR amplifi-
cation of env genes from single cDNA/proviral template mol-
ecules was then performed. A total of 132 env single molecule
amplicons were generated, with a range of 20 to 35 amplicons
per patient. Multiple sequences from each patient were used to
elucidate the infecting subtype/CRF. United Kingdom patients
UKBH1 and E21 were infected with subtype B viruses, Cam-
eroonian patients KM11 and KM18 harbored CRF02_AG vi-
ruses, while Cameroonian patient KM34 was infected with a
group M virus which did not correspond to any described
subtype/CRF (Table 1). To ensure patient KM34 was infected
with a group M strain, rather than group N or O viruses which
also cocirculate in Cameroon, a confirmatory phylogenetic
analysis with a panel of HIV-1 group M, N, and O reference
strain env genes was conducted. This analysis confirmed KM34
env genes clustered firmly within the group M radiation (data
not shown).
Length polymorphism and nucleotide sequence divergence.
The variable regions of env exhibit marked length variability
and the length of the V1/V2 region has been shown to influ-
ence receptor affinity, cellular tropism, and sensitivity to neu-
tralization. Consequently, the median lengths of gp160 pro-
teins encoded by env genes derived from different tissue
compartments were compared for each patient’s viral popula-
tion (see Fig. S1A in the supplemental material). Analysis of
compartment-specific viral populations from patient E21
showed that the brain-derived population had more compact
env coding regions compared to viruses derived from lymph
node. In patient KM18 the median length of semen-derived
gp160 was greater than blood-derived gp160, while this trend
was reversed for patient KM34. The overall length of the env
genes for patients UKBH1 and KM11 were not significantly
different between anatomic sites.
Patient-specific alignments were then gap stripped, and pair-
FIG. 1. Phylogenetic assessment of env compartmentalization from immunologically discrete tissues. A midpoint-rooted ML phylogenetic
reconstruction for the combined HIV-1 env alignment generated using the GTRI4 substitution model (74, 88, 89) is shown. Branch lengths
are in accordance with the scale bar and are proportional to genetic distance. Significance of clustering of isolates was assessed via bootstrap
resampling of the sequence data derived from 1000 replications. *, Values 70%; **, values 99%. Isolates marked with a “” were selected for
subsequent phenotyping.
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wise nucleotide sequence divergences were calculated for each
patient’s compartment-specific pool of env variants. The aver-
age substitutions per site were calculated for all sequence pairs
derived from each tissue compartment and plotted (see Fig.
S1B in the supplemental material). Median pairwise distances
were generally lower in brain compared to lymph tissue and in
semen compared to blood.
Phylogenetic assessment of intrahost compartmentaliza-
tion. To assess the specific patterns of HIV-1 compartmental-
ization in each infected individual, phylogenetic analyses were
conducted. All env sequences were aligned in a combined data
set to enable identification of possible cross-contamination
events. The env sequences clustered into five patient-specific
monophyletic clades which exhibit various degrees of intrahost
compartmentalization (Fig. 1). Patient KM11’s sequences ex-
hibited monophyletic blood- and semen-derived HIV-1 popu-
lations and a third population containing sequences derived
from both compartments. Topologically, the extent of com-
partmentalization observed in patient’s E21 and KM34 was
identical, with two distinct sequence populations observed. In
both patients, all sequences of one type form a clade within the
radiation of sequences of the other type. These distinct se-
quence populations were largely correlated with tissue com-
partment. KM18 exhibited almost complete compartmental-
ization of env variants, although low-level migration of virus
and/or infected cells between tissue compartments was also
detected. Finally, there was no evidence of compartmentaliza-
tion of blood- and semen-derived sequences obtained from
patient UKBH1.
Intercompartment recombination. The results of partition
incongruence tests (19) showed that different regions of the
env gene were topologically incongruent in all patients (P 	
0.05), which is indicative of recombination events. Therefore,
to assess this further, the trees generated during the incongru-
ence analysis were manually inspected for significant positional
shifting of isolates between compartment specific clades in
different regions of env: a signature of intercompartment re-
combination. Utilizing this method, we identified a total of
eight putative intercompartment recombinants in 3 patients
(E21, n 
 4; KM11, n 
 1; KM34, n 
 3; see Fig. S2 in the
supplemental material). There was no compelling evidence for
intercompartment recombination in patients UKBH1 and
KM18. Assignment of parental sequences was achieved via
iterative manual generation of informative site arrays (55, 72),
with every possible combination of parental sequences tested
against each putative mosaic. The two sequences that in com-
bination gave the highest number of informative sites were
designated parental strains of the recombinant virus. The sub-
sequent location of breakpoints and the corresponding P val-
ues were determined via a combination of parental strain di-
versity plot crossover points, and informative site array
position which maximized the 2 value (Fig. 2 and Table 2).
Three variants derived from the brain of patient E21
(E21BrD46, E21BrD92, and E21BrD100) had fragments of
the gp41 coding region that were more similar to those present
in lymph-derived sequences. A fourth sequence obtained from
brain (E21BrD107) was a mosaic virus that possessed frag-
ments containing V1/V2 and gp41 sequences from a brain-
derived parental strain and the remaining env coding region
representative of lymph-derived variants. Phylogenetic trees
corresponding to each of these fragments can be seen in Fig. 3,
with the positional shifting of env E21BrD107 between com-
partment specific clades highlighted. Patient KM11 harbored a
recombinant virus present in blood which possessed a V1/V2
loop (plus flanking regions) homologous to sequences ob-
served in the seminal population. Finally, three further recom-
binants were identified in patient KM34, where semen variants
contained either V1/V2 (KM34SeR63) or C3 (KM34SSeR3
and KM34SeR54) sequences corresponding to blood-derived
virus (see Fig. 2).
Phenotypic characterization. We next assessed whether
there were differences in the phenotypes of viruses present in
each tissue compartment and whether the characterized re-
combination events affected phenotype. Full-length env se-
quences representative of the tissue compartment specific
gp160s, plus the identified intercompartment recombinants
from patients E21 and KM34, were cloned into a mammalian
expression vector. Resulting gp160 clones were used in fusion
and pseudoparticle entry assays to investigate coreceptor us-
age, macrophage tropism, and sensitivity to a range of entry
inhibitors and neutralizing antibodies that block viral entry. A
summary of these data can be seen in Table 3. The majority of
the clones analyzed used the CCR5 coreceptor. Two clones,
one derived from the lymph tissue of E21, which was repre-
sentative of a minor group of lymph sequences that possessed
an unusual V3 loop apical sequence with a triplet amino acid
insert (GPG), plus a blood-derived sequence from patient
KM34, both utilized CXCR4.
Macrophage tropism. We next investigated how efficiently
R5 gp160s could mediate infectivity of primary macrophages.
Figure 4 presents macrophage infectivity of pseudovirions as a
percentage of infectivity in HeLa TZM-BL cells. A macro-
phage infectivity of 1% was considered macrophage-tropic.
Compartmentalization of macrophage tropism was evident be-
tween lymph node/brain- and blood/semen-derived viruses
from patients E21 and KM34, respectively. All but one of the
E21 brain-derived gp160s conferred higher macrophage infec-
tivity than those derived from lymph node. The exception was
E21BrD9, which exhibited substantially reduced macrophage
tropism (0.49%) compared to other brain isolates (7.55 to
25.94%). Comparison of its sequence with the other brain-
derived sequences showed that the former had an additional
two amino acid deletion and loss of the potential N-linked
glycosylation (PNG) site at position N186 in the V2 loop, a
region which has been previously shown to be important in
conferring macrophage-tropism (83). The two recombinant vi-
ruses obtained from E21 brain were both macrophage-tropic.
R5 macrophage tropism is modulated by polymorphisms in the
CD4 contact residues (30, 49) and residues that affect CD4
binding site exposure. These include residues flanking the CD4
binding site (16), an E153G substitution in V1 (43), and the
presence of an asparagine at residue 283 (18, 50). Two CD4
contact residues (residues 281 and 455) (30), plus an additional
residue (residue 291) thought to modulate macrophage tro-
pism (16), exhibit compartment specific differences between
brain- and lymph-derived sequences (Fig. 5A). Recombinant
brain-derived gp160 E21BrD107 is highly macrophage-tropic
and yet possesses identical residues to those found in the
non-macrophage-tropic lymph-derived sequences at these po-
sitions. However, large differences in the length and number of
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PNG sites between lymph node and brain V1/V2 loops were
observed. Lymph node V1/V2 loops possessed an average of 70
amino acids and 6 PNG sites, while brain V1/V2s loops were
more compact, with an average of 60 amino acids and 5 PNG
sites. Together, these data suggest the major determinants of
macrophage tropism in patient E21 are located in the V1/V2
loops.
Blood-derived gp160s from patient KM34 were generally
non-macrophage-tropic or conferred low levels of macrophage
tropism, while semen-derived gp160s were either highly mac-
rophage-tropic or non-macrophage-tropic (Fig. 4). Despite dif-
ferences in macrophage tropism, residue N283, CD4 contact
residues, and other residues implicated in modulating macro-
phage tropism did not exhibit compartment specific differ-
ences, although some variability was observed. Inspection of
the encoded gp160 proteins revealed the observed range of
tropism in patient KM34 is likely to be modulated by differ-
ences in the V1/V2 region, where substantial differences in the
length and number of PNG sites between blood- and semen-
derived V1/V2 loops were observed (Fig. 5B). Blood V1/V2
loops possess an average of 66 amino acids with 6 PNG sites,
while semen V1/V2 loops are more compact, with an average
of 57 amino acids and 5 PNG sites (see Fig. 5B). Recombinant
semen envelope KM34SeR63 had a blood-like V1 loop and
exhibited a 50-fold reduction in macrophage tropism (0.76%)
compared to semen-derived KM34SeR3 (recombinant, blood-
like C3 region, 37.40%) and KM34SeR33 (nonrecombinant,
39.11%). Indeed, nonrecombinant seminal isolate
KM34SeR33 is identical to recombinant KM34SeR63 at all
gp120 residues outside the V1 loop (see Fig. 5B). These data
FIG. 2. Evidence for intercompartment mosaicism. Example similarity plots and informative site arrays were used to characterize intercom-
partment mosaics. Plots were generated in SimPlot with a sliding window size of 200 bp and a step size of 20 bp and represent a query mosaic
compared to two parental sequences. Dotted vertical lines indicate absolute breakpoint positions correlated with diversity plot crossover points.
Associated P values (*, P 	 0.05; **, P 	 0.01; ***, P 	 0.001) are derived from informative site arrays (described in Materials and Methods and
displayed in Table 2). Relative numbers of informative sites shared by query sequences with parental strains are displayed below regions of
differential homology. Four taxon trees consistent with these sites are displayed to the left: QS, query sequence; PS1, parental sequence 1; PS2,
parental sequence 2; OG, outgroup. (A) Query mosaic E21BrD107 compared to parental sequences E21BrD90 and E21LnD56. (B) Query mosaic
KM11BlR7 compared to parental sequences KM11BlR22 and KM11SeR2. (C) Query mosaic KM34SeR63 compared to parental sequences
KM34BlR11 and KM34SeR26. (D) Schematic diagram depicting breakpoint locations in eight characterized mosaics, displayed relative to the
positions of functionally defined regions in the HXB2 reference env located above. The patient from which each mosaic was isolated is detailed
to the right of each individual recombinant env schematic. Regions of differential homology are color coded.
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indicate a blood-like V1 loop in a seminal background renders
gp160 KM34SeR63 non-macrophage-tropic and demonstrate
cellular tropism modulation due to intercompartment env re-
combination.
Maraviroc sensitivity. The CCR5 antagonist maraviroc
demonstrates potent antiviral activity against R5-tropic pri-
mary isolates derived from diverse clades (14). As expected,
the X4 gp160s KM34BIR71 and E21lnD43 were highly resis-
tant to this entry inhibitor (Table 3 and Fig. 6). In contrast all
of the R5 gp160s tested exhibited sensitivity to maraviroc (50%
inhibitory concentration [IC50] range, 0.08 to 1.33 nM), regard-
less of tissue origin. In patient E21, compartmentalization of
sensitivity to maraviroc was observed. Nonrecombinant brain-
derived gp160s were highly sensitive (mean IC50 
 0.18 nM),
while lymph node R5 isolates exhibited 5-fold less sensitivity
(mean IC50 
 1.06 nM). Sensitivity to maraviroc can be mod-
ulated by sequence differences in the V3 loop, which is the
principle determinant for CCR5 coreceptor binding. Amino
acid residues that differed between brain- and lymph-derived
sequences were located at positions L309I, G315R, T319A,
TABLE 2. Putative breakpoints of intercompartment recombinants
Mosaic sequence No. ofbreakpoints Parental sequences Region
a No. of
supporting sites
Breakpoint
positiona P
E21BrD46 1 E21BrD82 1–1956 22 2101 	0.0001
E21LnD10 2161–2571 6
E21BrD92 1 E21BrD62 1–1650 22 1846 	0.0001
E21LnD13 1931–2571 7
E21BrD100 1 E21BrD119 1–2127 26 2210 	0.0001
E21LnD43 2217–2571 4
E21BrD107 3 E21BrD90 1–253 2 262 0.0442
E21LnD56 364–687 8 775 	0.0001
E21BrD90 829–1392 16 1515 0.0056
E21LnD56 1650–2571 8
KM11BlR7 2 KM11BlR22 1–93 2 219 0.0365
KM11SeR2 394–848 9 864 0.0004
KM11BlR22 914–2571 23
KM34SeR3 2 KM34SeR21 1–837 17 911 0.0004
KM34BlR71 1017–1080 4 1164 0.0569
KM34SeR21 1227–2571 3
KM34SeR54 2 KM34SeR49 1–837 14 905 0.0007
KM34BlR71 1017–1080 4 1173 0.0286
KM34SeR49 1227–2571 4
KM34SeR63 2 KM34SeR26 1–238 3 319 0.0356
KM34BlR11 363–450 5 551 0.0010
KM34SeR26 557–2571 9
a The coordinates are given relative to the nucleotide position in the HXB2 reference strain env gene.
FIG. 3. Phylogenetic trees corresponding to regions of differential homology in intercompartment mosaic E21BrD107. Patient E21’s env
alignment was divided into four segments, in agreement with the three breakpoints identified in isolate E21BrD107, and ML phylogenetic trees
were constructed for each segment: positions 1 to 262 (A), positions 263 to 774 (B), positions 775 to 1514 (C), and positions 1515 to 2571 (D).
Highlighted isolate E21BrD107 exhibits significant positional shifting between compartment specific clades.
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and Q322E (Fig. 5A). Intercompartment mosaic E21BrD107
contains a lymph node-like V3 loop (see Fig. 2) and possesses
lymph node-like sensitivity to maraviroc (IC50 
 1.19 nM,
Table 3 and Fig. 6). Together, these data indicate compart-
ment specific differences in sensitivity to maraviroc in patient
E21 and demonstrate maraviroc sensitivity switching due to
intercompartment env mosaicism. In patient KM34, there was
limited variability in the V3 loop sequences of blood- or se-
men-derived isolates (Fig. 5B), and all of the R5 gp160s de-
rived from this patient had similar maraviroc sensitivity.
Soluble CD4 sensitivity. Previously, we demonstrated that
R5 macrophage tropism is significantly correlated with in-
creased sensitivity to sCD4, which is compatible with increased
exposure of the CD4 binding site and/or substitutions which
confer tighter CD4 binding (49). The macrophage-tropic
gp160s derived from brain and semen samples of patients E21
and KM34 were highly sensitive to entry inhibition by sCD4,
whereas the non-macrophage-tropic gp160s derived from cor-
responding lymph node and blood were demonstrably less sen-
sitive to sCD4 entry inhibition (Table 3). Intercompartment
recombination had minimal effect on the sensitivity to sCD4
inhibition.
Sensitivity to broadly neutralizing antibodies IgG1-b12
(b12) and 2G12. The monoclonal antibody b12 binds to a
conformational conserved epitope on gp120 overlapping a dis-
crete subset of CD4 contact residues (91). Previous data has
shown that subtype B macrophage-tropic brain-derived gp160s
are more sensitive to b12 than non-macrophage-tropic lymph
tissue-derived gp160s (17, 49). In complete contrast to these
findings, the non-macrophage-tropic lymph-derived gp160s
from patient E21 were highly sensitive to b12 neutralization,
while brain gp160s exhibited b12 resistance (Table 3). Regu-
lation of b12 sensitivity, albeit in CRF01_AE viruses, has been
linked to two N-linked glycan sites at amino acid positions 186
and 197 in the V2 and C2 regions (78) (Fig. 5A). Mosaic
envelope E21BrD107 is similar to lymph-derived gp120s across
nearly all regions except the V1V2 region (Fig. 2) and yet
maintains a brain-like b12-resistant phenotype. Together,
these data suggest the determinants contributing to b12 resis-
tance/sensitivity in patient E21 gp160s are located in one or
more of the V1/V2/C2 regions. The gp160s from patient KM34
(non-subtype B) were largely resistant to b12 inhibition, irre-
spective of their macrophage tropism or source.
The monoclonal antibody 2G12 targets a carbohydrate
TABLE 3. Phenotypic properties of patient-derived gp160s
gp160a Sample material Coreceptor usage
Propertyb
Macrophage
tropism
Maraviroc
sensitivity
sCD4
sensitivity
b12
sensitivity
2G12
sensitivity
E21LnD4 Lymph node CCR5 –    
E21LnD10 Lymph node CCR5 –    
E21LnD17 Lymph node CCR5 –    
E21LnD24 Lymph node CCR5 –    
E21LnD43 Lymph node CXCR4 – –   
E21LnD58 Lymph node CCR5 –    
E21BrD2 Brain CCR5    – –
E21BrD9 Brain CCR5 –   – –
E21BrD37 Brain CCR5    – –
E21BrD82 Brain CCR5    – –
E21BrD62 Brain CCR5    – –
E21BrD100 (R) Brain CCR5    – –
E21BrD107 (R) Brain CCR5    – –
KM34BlR14 Blood CCR5 –    
KM34BlR43 Blood CCR5    – –
KM34BlR52 Blood CCR5    – –
KM34BlR66 Blood CCR5 –  – – 
KM34BlR70 Blood CCR5 –  – – –
KM34BlR71 Blood CXCR4 – – – – –
KM34SeR3 (R) Semen CCR5    – –
KM34SeR33 Semen CCR5    – –
KM34SeR63 (R) Semen CCR5 –   – –
a (R), characterized recombinant gp160.
b Macrophage tropism is scored as follows: , 	1%; , 1 to 5%; , 5 to 15%; and , 15% infectivity in HeLa TZM-BL cells. Maraviroc sensitivity (nM)
is scored as follows: , IC50 
 	0.25; , IC50 
 0.25 to 1.0; , IC50 
 1; and , CXCR4 user. sCD4, b12, and 2G12 sensitivity (g/ml) is scored as follows:
, IC50 
 	10; , IC50 
 10 to 20; , IC50 
 20 to 50; and , 50.
FIG. 4. Macrophage tropism of HIV-1 gp160s amplified from an-
atomically discrete tissues. Patient/tissue-specific gp160s were ex-
pressed on HIV-1 pseudovirions. env pseudovirions were titrated on
HeLa TZM-BL cells and on primary macrophages. Macrophage in-
fectivity is expressed as a percentage of HeLa TZM-BL cell infectivity.
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epitope, primarily in subtype B viruses, composed of high-
mannose/hybrid glycans in the C2, C3, C4, and V4 domains
(64). Lymph node-derived gp160s from patient E21 were sus-
ceptible to 2G12 neutralization, while brain-derived gp160s
were resistant (Table 3). PNG sites at N295, N332, N339,
N386, N392, and N448 are reportedly important for 2G12
binding (38, 49, 64, 66). The PNG site at position 332 is absent
from E21 brain-derived gp160s but present in lymph node-
derived gp160s. However, the brain-derived mosaic
E21BrD107 has a PNG site at position N332 and yet a 2G12-
resistant phenotype, suggesting that 2G12 resistance exhibited
by E21 brain-derived gp160s is associated with determinants
other than those previously described. Indeed, lymph node
gp160s contain an extra PNG site in the V2 loop between N186
and N197 (see Fig. 5A), which may confer susceptibility to
2G12. Mosaic envelope E21BrD107 was similar to brain iso-
FIG. 5. Amino acid sequence alignments for functional gp160s. Functional gp160s from patient E21 (A) and patient KM34 (B) are aligned
relative to the HXB2 reference strain, and all residue numbering is relative to homologous positions in HXB2 gp160. Within the alignment,
asparagine (N) residues that are likely to be glycosylated have been replaced by “#”. Horizontal lines located above alignment segments indicate
the position of the variable regions V1 to V5. Symbols or letters located directly above alignment segments highlight the functionally important
residues: *, CD4 contact residue; m, additional residue previously implicated in modulation of macrophage tropism; b, residue previously
implicated in modulating sensitivity to b12; and g, residue previously implicated in modulating sensitivity to 2G12.
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lates across V1/V2 and therefore lacked this extra glycan and
had a 2G12-resistant phenotype. Together, these data indicate
compartmentalization of sensitivity to 2G12 in patient E21 and
suggest that contributory determinants of 2G12 resistance are
located in the V2 loop. While the majority of gp160s from
KM34 were 2G12 resistant, two blood-derived viruses
(KM34BlR14 and KM34BlR66) were highly sensitive to entry
inhibition by this antibody (Table 3). Both of these gp160s
possess an additional PNG site in the V5 region compared to
other KM34 isolates. These data suggest sensitivity to 2G12 in
patient KM34 is correlated to an additional PNG site in the V5
region.
DISCUSSION
Previous studies have demonstrated HIV-1 intrahost genetic
compartmentalization between numerous tissues (1, 4, 10, 12,
24, 27, 42, 47, 51–53, 63, 67, 79, 93). HIV-1 recombination at
the intersubtype (6), intrasubtype (58), and intrahost level (7,
45) has also been described. However, studies assessing HIV-1
intrahost compartmentalization have largely failed to investi-
gate the contribution of recombination to the evolution of
genetically discrete strains within an individual patient. More-
over, the impact of intrapatient genetic mosaicism on viral
phenotype, particularly within the envelope gene, has previ-
ously been entirely overlooked. We hypothesized that inter-
compartment env mosaic viruses would arise in vivo. Also,
given the divergent nature of compartmentalized sequences,
we reasoned that any putative intercompartment mosaics
would be readily detectable. In the present study we have
shown that intercompartment recombination is frequent in the
evolution of HIV-1 env in infected patients. In addition, we
report that some of these recombination events confer new and
potentially advantageous combinations of phenotypic traits
upon the recombinant progeny compared to nonrecombinant
parental strains.
Many previous studies assessing intrahost compartmental-
ization have utilized bulk amplification, cloning and sequenc-
ing strategies or have utilized viruses selected for growth in
vitro. These methods are subject to numerous biases and in
vitro artifacts which directly affect datasets generated and the
subsequent interpretation of patterns of sequence evolution
(62, 73, 80, 81). In addition, compartmentalization studies of-
ten utilize relatively small fragments of env (V1-V3 or C2-V5),
reducing the chances of detecting putative recombination
events in highly similar sequences. To minimize any experi-
mentally induced biases and maximize the phylogenetic signal
apparent in our data set, as well as facilitating phenotypic
analyses, we utilized full-length env sequences amplified from
single molecule templates derived directly from paired patient
tissue samples. This methodology has been demonstrated to
minimize polymerase induced misincorporations, reducing ar-
tificial inflation of intrahost viral diversity. If introduced in the
initial rounds of amplification, the signatures of polymerase
induced errors are easily identifiable since they appear as dual
peaks in the sequence chromatographs. If introduced in the
later rounds of amplification, misincorporations remain unde-
tected since they represent only a minor component of gener-
ated amplicons (62). Critically, viral sequences generated in
this manner are not subject to in vitro recombination events,
which occur via polymerase template switching during bulk
amplification from multiple starting templates (42, 62, 70).
Numerous phylogenetic and statistical tests can be used to
assess degrees of HIV-1 intrahost compartmentalization. How-
ever, genetic mosaicism has been shown to adversely affect the
results of these tests (90). Furthermore, identifying recombi-
nant sequences in datasets derived from highly related variants
is challenging. Automated procedures for the detection of re-
combination implemented in GARD (28, 29) identified nu-
merous significant breakpoints in all datasets, as defined by
discordant topologies, but lacked the facility to identify paren-
tal strains requiring subsequent manual investigation of the
sequence data. Intercompartment mosaics breakpoints and pa-
rental strains could be correctly detected in via tests used in
RDP2 (40). However, disparate results were obtained using
the various tests used in this program, which required some
prior knowledge of the likely recombinants and parental
strains for correct interpretation of the output data. Conse-
quently, we utilized an iterative approach involving manual
inspection for topological incongruence in trees derived from
different regions of env. Pairwise diversity plots and informa-
tive site arrays then enabled high-resolution identification of
breakpoints and parental sequences. A number of breakpoints
within env were identified across the intercompartment recom-
binant forms we characterized. Although specific breakpoint
hot spots were not obvious, breakpoint locations generally
occurred in the more conserved regions of env or were located
at gp120 conserved/variable region boundaries. Breakpoint lo-
cations were generally in agreement with intersubtype break-
point hot spots identified by in vitro modeling and in vivo
observations (71). This is despite the fact that predicted con-
straints, such as maintenance of protein fold, are likely to be
less severe at the intrahost level compared to the intersubtype
level: viral variants circulating within a host infected with a
single strain possess limited diversity while different group M
subtypes can differ by up to 38% in envelope amino acid
identity (82). All of the recombinant gp160s tested were shown
to be functional in pseudotype assays, indicating that the char-
acterized recombination events resulted in no deleterious dis-
ruption of gp160 tertiary or quaternary conformation and sta-
bility. In addition, it is likely that genomic constraints may also
influence patterns of HIV-1 env recombination. Secondary
FIG. 6. Sensitivity of HIV-1 gp160s to maraviroc. Patient/tissue-
specific env pseudovirions were tested for sensitivity to entry inhibi-
tion by maraviroc.
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RNA structures apparent in the env gene region (84) may
favor/inhibit certain recombination events in naturally circu-
lating virus. Variable loop regions (V1 to V5) in gp120 are
reported to contain largely unstructured genomic RNA but are
bordered by evolutionary conserved RNA structures in the
conserved regions (84). Our identified breakpoints were gen-
erally observed in conserved regions or at conserved/variable
region boundaries. Mosaic genomes that result in disruption to
gp160 protein conformation or evolutionary conserved
genomic RNA elements will be deleterious and removed from
populations via purifying selection.
Viruses circulating in the peripheral blood or present in
lymph nodes evolve to occlude critical regions, such as receptor
binding sites, from host neutralizing antibodies. The blood-
brain barrier and blood-testes barrier restrict the passage of
neutralizing antibodies, making the brain and testes immuno-
privileged tissues (5). Similarly, the type and frequency of
HIV-1 permissive cells differs between sites, and the relative
availability of CD4 and coreceptors on these target cells is
likely to influence their permissiveness for different strains (49,
50). Consequently, viruses replicating in the brain or semen are
likely to evolve in response to their unique environment, ac-
quiring tropism and receptor affinity appropriate to each niche.
Our analyses show that compartmentalization can be associ-
ated with altered macrophage tropism and sensitivity to entry
inhibitors and monoclonal neutralizing antibodies. Crucially,
our data has shown that these phenotypes can be altered by
intercompartment recombination events. For example, recom-
binant brain isolate E21BrD107, which possesses a lymph
node-like C2-C5 region, maintained the macrophage tropism
of nonrecombinant brain-derived gp160s but acquired a re-
duced sensitivity to maraviroc through acquisition of V3 loop
represented in lymph node-derived gp160. In addition, in pa-
tient KM34, blood-derived viruses were non-macrophage-
tropic or poorly macrophage-tropic, whereas semen-derived
gp160s were highly macrophage-tropic. However, recombinant
semen envelope KM34SeR63, which possessed a region of
gp120 encompassing the V1 loop present in blood-derived
gp160s, was non-macrophage-tropic.
At the population level, the wide global dissemination of
multiple intra- and intersubtype CRFs indicates recombinant
genomes may possess a fitness advantage compared to pure
subtypes in certain environmental settings. At the intrahost
level, intercompartment recombination represents an addi-
tional molecular mechanism for generating viable and poten-
tially fitter viral variants. Our study reveals the genetic signa-
tures of intercompartment mosaicism are readily detectable in
viruses isolated from different tissues, indicating this process
occurs frequently in infected individuals. Indeed, although the
present study was on a relatively small scale, with five patient’s
viral populations investigated, intercompartment mosaicism
was detected in three individuals, with recombinant env genes
comprising between 2 to 11% of generated amplicons. Our
study was limited to viruses amplified from two tissue compart-
ments per patient derived from a single time point, and char-
acterization of recombinant isolates was restricted to those
where both parental strains were represented in the popula-
tion. Consequently, as HIV-1 is reported to be present in
multiple tissue types, it is likely that intercompartment recom-
bination occurs at rates in excess of those reported herein.
Investigation of the functional consequences of the shuffling of
phenotypic traits suggests this process may facilitate viral im-
mune evasion and development of resistance to entry inhibi-
tors. Viral progeny generated in this manner possessing advan-
tageous combinations of traits will be rapidly swept to fixation
within an infected host.
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